
- Vol 38, Issue 9
Harnessing Harm-Reduction Methods to Combat the Opioid Crisis
CLINICAL REFLECTIONS
Fentanyl and fentanyl analogues, such as carfentanil, are driving an opioid overdose crisis in North America.1 In 2019 alone, there were 3831 opioid-related deaths in Canada2 and 47,600 fatalities involving opioids in the United States (
OAT clinics often lack psychosocial supports and, frequently, high out-of-pocket expenses prove problematic for individuals with OUD who have limited financial means.7 Similar economic, geographic, attitudinal, and organizational barriers exist in the United States.7 Additionally, in the United States, where public insurance providers favor methadone whereas private insurance providers favor buprenorphine/naloxone, health insurance barriers have caused rampant racial and economic disparities in OAT access across the country.8
Since the start of the
Historically, the success of harm-reduction services for OUD has been difficult to quantify; most studies have small sample sizes and poorly defined outcome measures. These studies have limited generalizability to most individuals with OUD, who respond to first-line treatments. However, mounting evidence demonstrates proof of efficacy and effectiveness for a range of harm-reduction services. Recent studies have shown that they can reduce opioid overdose mortality, infection-related complications, and crime commitment among individuals with treatment-refractory OUD (TR-OUD).9
In recent years, Canadian health care providers have implemented 3 critical harm-reduction measures that have curtailed opioid-related fatalities: (1) heroin-assisted treatment (HAT), (2) hydromorphone-assisted therapy, and (3) SCFs.
We advocate for the provision of substantiated harm-reduction services in the United States that, following the Canadian example, could save countless lives by increasing access to evidence-based treatment options for OUD.
Heroin-Assisted Treatment
HAT, or heroin maintenance, is an evidence-based intervention for managing the symptoms of TR-OUD. Although definitions of TR-OUD vary, most studies refer to the failure to respond meaningfully to 1 or more first-line treatments for OUD (eg, methadone or buprenorphine/suboxone). HAT is available in Canada (eg, Vancouver and Montreal) and some European countries (eg, Germany, Switzerland, and the United Kingdom) and has shown efficacy in select groups experiencing TR-OUD. To receive HAT, individuals with TR-OUD visit a designated HAT clinic, where they receive injectable medical-grade heroin (diacetylmorphine) up to 3 times daily under strict nursing and medical supervision.10 In essence, most HAT clinics operate under a supervised consumption model.
Results from randomized controlled trials have shown promising findings for individuals with TR-OUD. In one trial, HAT reduced illicit heroin use, improved treatment retention, reduced criminal activities, and improved mental and physical health compared with methadone therapy.11 While HAT is more expensive than oral methadone treatment, the social and economic benefits justify its provision for select patients with TR-OUD who have not benefited from first-line therapies. Nonetheless, studies have shown an association between HAT and a higher risk of adverse events such as seizures and opioid overdoses11 than methadone or
Injectable Hydromorphone
Given the regulatory restrictions in providing HAT, investigators in Vancouver, British Columbia, considered alternative strategies for treating individuals with TR-OUD. The search for alternative OAT led to hydromorphone, a synthetic opioid used to treat chronic pain. Consequently, researchers at St Paul’s Hospital in Vancouver conducted the Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) trial.
In brief, the SALOME trial was an innovative study investigating the use of injectable hydromorphone (IH) as an alternative to intravenous diacetylmorphine (eg, HAT) for TR-OUD. The researchers aimed to establish the noninferiority of IH to HAT. Ultimately, the researchers found that delivering the 2 interventions under the same conditions (eg, supervised consumption facilities) led to positive outcomes in both groups. For example, participants receiving either treatment showed improved treatment retention, greater global functioning, reduced illicit opioid use, and diminished illegal activities.12,13 The SALOME trial was among the first to establish the efficacy of these harm-reduction measures for individuals with TR-OUD. Consequently, the SALOME trial results suggest that when diacetylmorphine is unavailable or other treatments are unsuccessful, IH can be a suitable alternative for treating severe TR-OUD.
In January 2019, Vancouver started the first hydromorphone tablet distribution program, based on the SALOME trial’s promising results. A qualitative study evaluated the program’s effects suggested that it can decrease illicit drug use,
The SCFs
SCFs were first developed in response to the HIV epidemic in Vancouver when Insite—North America’s first SCF—proved to be a tremendous asset in combating the opioid crisis.9 SCFs also provides a multifaceted opportunity to address comorbidities, such as psychiatric illness, HIV/AIDS, and other infectious diseases. Because individuals with TR-OUD frequently experience co-occurring medical and psychiatric disorders, SCFs have created critical opportunities to engage with a population that can be otherwise difficult to reach. Studies have demonstrated the myriad benefits of SCFs, such as decreasing rates of overdose deaths, crime, and infectious disease transmission, while remaining cost-effective.9
A recent study estimated the cost and impact of establishing SCFs in New York City. The results showed that an SCF could prevent 19 to 37 opioid overdose fatalities per year in that city, and save its health care system between $831,700 and $2.9 million as well.15 However, the establishment of SCFs remains controversial in the United States, and advocacy for drug policy changes must continue.
Conclusions
The
The rising number of opioid-related fatalities is a call to action to implement sustainable measures to prevent overdose occurrences beyond acute naloxone administration. Canada has implemented multiple harm-reduction measures since the beginning of its opioid crisis, which have reduced overdose mortality. For example, the current safe-supply programs focus on prescribing pharmaceutical-grade opioids, such as injectable hydromorphone and diacetylmorphine, to individuals who are at high risk of opioid overdose. This strategy is powerful in reducing the harms caused by fentanyl-related opioids on the illicit drug market, and as a result, overdose events have been prevented and overdose mortality has been decreased.1 Canadian and international studies on SCF have shown that the facilities are effective in reducing overdose fatalities, needle sharing, unsafe injection practices, and involvement in criminal activities.9
As Canada and the United States seek comprehensive, collaborative, and evidence-based approaches to combat the current opioid crisis, they each can learn from the collective expertise and strategies implemented on the other side of the border.
Ms Izadi is a third-year medical student at Touro College of Osteopathic Medicine in New York. Dr Bahji is a fellow in addiction psychiatry at the University of Calgary’s Cumming School of Medicine. Dr Chopra is a staff psychiatrist in the addictions division at the Centre for Addiction and Mental Health (CAMH) and a lecturer in psychiatry, Temerty Faculty of Medicine, University of Toronto. Ms Ling is an advanced practice clinical leader at CAMH, and a PhD candidate in the Bloomberg School of Nursing at the University of Toronto. Dr Hansen is professor of anthropology and psychiatry, and research chair in the social medicine theme, at UCLA’s David Geffen School of Medicine, Los Angeles. Dr George is professor of psychiatry in the Temerty Faculty of Medicine at the University of Toronto and a clinician-scientist in the addictions division of CAMH in Toronto. He also serves as deputy editor of the journal Neuropsychopharmacology.
Acknowledgments - The constructive and critical comments of Eric C. Strain, MD, of John Hopkins University on the manuscript are gratefully acknowledged.
References
1. Ivsins A, Boyd J, Beletsky L, McNeil R.
2. Opioid- and stimulant-related harms in Canada [maps]. Government of Canada. June 2021. Accessed July 22, 2021.
3. Overdose death rates. National Institute on Drug Abuse. Updated January 29, 2021. July 22, 2021.
4. Opioid- and stimulant-related harms in Canada [key findings]. Government of Canada. Updated June 2021. Accessed July 22, 2021.
5. Overdose deaths accelerating during COVID-19. News release. CDC; December 17, 2020. Accessed July 22, 2021.
6. Schuckit MA.
7. Priest KC, Gorfinkel L, Klimas J, et al.
8. Hansen HB, Siegel CE, Case BG, et al.
9. Young S, Fairbairn N.
10. Heroin-assisted treatment (HAT). Drug Policy Alliance. February 2016. Accessed July 22, 2021.
11. Oviedo-Joekes E, Brissette S, Marsh DC, et al.
12. Oviedo-Joekes E, Guh D, Brissette S, et al.
13. Timko C, Schultz NR, Cucciare MA, et al.
14. Ivsins A, Boyd J, Mayer S, et al.
15. Behrends CN, Paone D, Nolan ML, et al.
Articles in this issue
about 4 years ago
The State of Mental Health of Black Women: Clinical Considerationsabout 4 years ago
What Do I Do Now? Making Decisions in a Postpandemic Worldabout 4 years ago
A Generation in Crisis?about 4 years ago
Treating Mania in Older Adults With Bipolar Disorderabout 4 years ago
Inclusivity: Ensuring Patients Who Are Plus-Size Feel Welcomeabout 4 years ago
Art Imitating Life: A Poet’s Wordsabout 4 years ago
Fraternity Paddleabout 4 years ago
Exploring Possible Etiologies for Psychotic Disorders in Late LifeNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.